PET-Guided Resection in High-Grade Gliomas
NCT07567196 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2026-05-05
Summary
Background: Glioblastoma (GBM) is the most common primary brain tumor in adults, with a poor prognosis despite maximal treatment. Current evidence suggests that supramaximal resection, including non-enhancing FLAIR-hyperintense regions, improves survival. However, the extent of FLAIR resection is often limited by functional constraints and its non-specific nature, as it may represent both tumor infiltration and peritumoral edema. This study explores the role of 18F-DOPA PET in refining supramaximal resection by providing a more specific surgical target beyond contrast-enhancing areas.
Objective: To evaluate the impact of 18F-DOPA PET-guided resection on progression-free survival (PFS) and overall survival (OS) in GBM patients, by comparing outcomes between those undergoing PET-RM integrated resection versus conventional MRI-guided resection.
Methods: ResPGlioma is a multicenter, prospective, non-randomized study conducted at IRCCS Ospedale Policlinico San Martino (Genoa) and AOU Città della Salute e della Scienza (Turin). Patients with newly diagnosed, supratentorial, high-grade gliomas undergo preoperative 18F-DOPA PET and MRI. Surgery follows the principle of maximal safe resection, with postoperative MRI at 48 hours assessing the extent of resection (EOR). To confirm PET resection or non-PET resection status, patients will undergo a postoperative 18F-DOPA PET scan at 30 ± 7 days following surgery, prior to the initiation of chemoradiotherapy. Patients are categorized based on EOR criteria (RANO) and PET volume resection (PET-resection vs. PET non-resection). Statistical analyses include Kaplan-Meier survival curves and regression models to identify prognostic factors.Patients are categorized based on EOR criteria (RANO) and PET volume resection (PET-resection vs. PET non-resection). Statistical analyses include Kaplan-Meier survival curves and regression models to identify prognostic factors.
Expected Outcomes: The authors hypothesize that PET-guided resection improves PFS and OS by enabling a more precise tumor removal beyond contrast-enhancing margins while preserving neurological function. Preliminary data support that PET hypercaptant areas contain viable tumor cells and should be resected. This approach may offer a more accessible yet effective alternative to FLAIR-guided supramaximal resection.
Conditions
- Glioma Glioblastoma Multiforme
- Glioma, High Grade
- Glioma Surgery
- Positron-Emission Tomography(PET)
Sponsors & Collaborators
-
University of Turin, Italy
collaborator OTHER -
Universita degli Studi di Genova
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-04-01
- Primary Completion
- 2027-12-31
- Completion
- 2029-12-31
Countries
- Italy
Study Locations
More Related Trials
-
FMISO-PET in Brain Tumors and SCS Effect
NCT01868906 ·Status: TERMINATED ·Phase: PHASE2
-
Prognostic Impact of Surgical Resection Extent for Supratentorial High Grade Gliomas.
NCT03997136 ·Status: UNKNOWN
-
Predicting Sites of Tumour Progression in the Invasive Margin of Glioblastomas (PRaM-GBM Study)
NCT03294434 ·Status: COMPLETED
-
Application of FET-PET in Fusion With MRI in the Treatment of Glioblastoma Multiforme [TYR-GLIO]
NCT06466031 ·Status: RECRUITING ·Phase: NA
-
Impact of Surgery on the Treatment of Supratentorial Malignant Gliomas in Subjects Aged 70 and Over
NCT02892708 ·Status: COMPLETED ·Phase: PHASE3
-
Comparative Study of Intraoperative MRI-guided vs. Conventional Glioma Surgery
NCT01394692 ·Status: COMPLETED ·Phase: NA
-
Supramarginal Resection in Glioblastoma
NCT04243005 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
PH Sensitive MRI Based Resections of Glioblastoma
NCT06176066 ·Status: RECRUITING ·Phase: PHASE1
-
Safety and Imaging Study of GC1008 in Glioma
NCT01472731 ·Status: COMPLETED ·Phase: PHASE2
-
Glutamate Excitotoxicity and Its Role in Glioblastoma Biology
NCT05775458 ·Status: RECRUITING
-
Intraoperative Sonographically Versus Fluorescence-guided Resection of Contrast-enhancing Gliomas and Brain Metastases
NCT05475522 ·Status: SUSPENDED ·Phase: NA
-
Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid
NCT00241670 ·Status: COMPLETED ·Phase: PHASE3
-
Glioblastoma: Validation and Comparison Between Primary Tumor and Its Murine Model
NCT02904525 ·Status: UNKNOWN ·Phase: NA
-
Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma
NCT02176720 ·Status: TERMINATED ·Phase: PHASE1
-
Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma
NCT03770468 ·Status: COMPLETED
-
Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme
NCT01464177 ·Status: COMPLETED ·Phase: PHASE2
-
11C-Methionine PET as Prognostic Marker of Gliomas
NCT02518061 ·Status: COMPLETED
-
Brain Tumor Intraoperative Ultrasound Database
NCT05062772 ·Status: COMPLETED
-
Determination of Immune Phenotype in Glioblastoma Patients
NCT02751138 ·Status: COMPLETED
-
The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
NCT06146725 ·Status: RECRUITING
-
The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
NCT06273176 ·Status: RECRUITING
-
An Integrated Radio-immunological Approach
NCT05267509 ·Status: ACTIVE_NOT_RECRUITING
-
Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBM
NCT02780024 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Combined Approach to Resection of Glioblastoma (GBM) by 5-Aminolevulinic Acid (5-ALA) and Intraoperative Magnetic Resonance Imaging (MRI)
NCT01208909 ·Status: UNKNOWN
-
A Multicenter, Prospective Study for Glioblastoma Patients
NCT07162324 ·Status: NOT_YET_RECRUITING